Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | TACR1 | P25103 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.47 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.46 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.46 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.46 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.46 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL924299 | 1.00 | CYP2D6 (0.52) | CYP2D6CYP1A2CYP2C19TACR1SMN1; SMN2 | |
| SCHEMBL248882 | 1.00 | CYP2D6 (0.52) | CYP2D6CYP1A2CYP2C19TACR1SMN1; SMN2 | |
| SCHEMBL2785511 | 1.00 | CYP2D6 (0.52) | CYP2D6CYP1A2CYP2C19TACR1SMN1; SMN2 | |
| SCHEMBL3282010 | 0.92 | SLC6A2 (0.52) | CYP2D6CYP1A2CYP2C19TACR1SLC6A2 | |
| SCHEMBL12706002 | 0.90 | CYP1A2 (0.62) | CYP2D6CYP1A2CYP2C19SLC6A2TAAR1 | |
| SCHEMBL10804153 | 0.90 | CYP1A2 (0.62) | CYP2D6CYP1A2CYP2C19SLC6A2TAAR1 | |
| Lactic Acid SCHEMBL7771136 | 0.87 | PSMB5 (0.48) | CYP2D6CYP1A2CYP2C19SMN1; SMN2LMNA | |
| SCHEMBL468022 | 0.85 | EPHX1 (0.61) | CYP2D6CYP1A2CYP2C19SLC6A2TAAR1 | |
| SCHEMBL272604 | 0.85 | EPHX1 (0.61) | CYP2D6CYP1A2CYP2C19SLC6A2TAAR1 | |
| SCHEMBL3451169 | 0.85 | EPHX1 (0.61) | CYP2D6CYP1A2CYP2C19SLC6A2TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2360160-B1 | Intermediates and their use for producing benzoxazine derivative | DAIICHI SANKYO CO LTD (JP) | 2013-07-24 | — | — | EP | claimed |
| EP-2218722-B9 | Process for producing benzoxazine derivative and production intermediate thereof | DAIICHI SANKYO CO LTD (JP) | 2013-06-19 | — | — | EP | claimed |
| EP-2218722-B1 | Process for producing benzoxazine derivative and production intermediate thereof | DAIICHI SANKYO CO LTD (JP) | 2013-03-13 | — | — | EP | claimed |
| EP-2360160-A1 | Intermediates and their use for producing benzoxazine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-08-24 | — | — | EP | claimed |
| US-7087778-B2 | Process for producing benzoxazine derivative and production intermediate thereof | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-08-08 | — | — | US | claimed |
| US-20050027119-A1 | Process for producing benzoxazine derivative and production intermediate thereof | DAIICHI PHARMACEUTICAL CO., LTD. | 2005-02-03 | — | — | US | claimed |
| EP-1211254-A1 | PROCESS FOR THE PREPARATION OF BENZOXAZINE DERIVATIVES AND INTERMEDIATES THEREFOR | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2002-06-05 | — | — | EP | claimed |
| EP-0763513-B1 | Production of optically active 2-halo-1-(substituted phenyl)-ethanol and substituted styrene oxide | NIHON NOHYAKU CO LTD (JP) | 2001-11-14 | — | — | EP | claimed |
| JP-11279111-A | — | — | None | — | — | JP | disclosed |
| JP-11199542-A | — | — | None | — | — | JP | disclosed |
| US-20210228508-A1 | COMPOSITIONS AND METHODS THEREOF | Exciva GmbH | 2021-07-29 | — | — | US | disclosed |
| US-20140350301-A1 | NOVEL PROCESSES FOR THE PREPARATION OF PHENYLCYCLOPROPYLAMINE DERIVATIVES AND USE THEREOF FOR PREPARING TICAGRELOR | ACTAVIS GROUP PTC EHF (IS) | 2014-11-27 | — | — | US | disclosed |
| EP-1211254-B1 | Process for the preparation of benzoxazine derivatives and intermediates therefor | DAIICHI SANKYO CO LTD (JP) | 2014-05-07 | — | — | EP | disclosed |
| EP-2284174-B1 | Intermediates for the preparation of benzoxazine derivatives and process for their preparation | DAIICHI SANKYO CO LTD (JP) | 2014-03-05 | — | — | EP | disclosed |
| EP-0567271-A2 | Steroid derivatives for the treatment of prostatic hypertrophy, their preparation and uses | SANKYO COMPANY LIMITED (JP) | 1993-10-27 | — | — | EP | disclosed |
| EP-0508307-A2 | Optically active secondary amine compound; process for producing optically active secondary amine compound and process for producing optically active carboxylic acid by using said compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1992-10-14 | — | — | EP | disclosed |
| EP-0484094-A2 | Azasteroid compounds for the treatment of prostatic hypertrophy, their preparation and use | Sankyo Company Limited (JP) | 1992-05-06 | — | — | EP | disclosed |
| EP-0105745-B1 | PACKING MATERIALS FOR CHROMATOGRAPHIC USE AND THEIR EMPLOYMENT IN ANALYSING ENANTIOMERIC MIXTURES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1987-12-16 | — | — | EP | disclosed |
| US-4512898-A | ORGANOSILANE DERIVATIVES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1985-04-23 | — | — | US | disclosed |
| EP-0105745-A2 | Packing materials for chromatographic use and their employment in analysing enantiomeric mixtures | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1984-04-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140350301-A1 | NOVEL PROCESSES FOR THE PREPARATION OF PHENYLCYCLOPROPYLAMINE DERIVATIVES AND USE THEREOF FOR PREPARING TICAGRELOR | THPO, P2RY4, TBXA2R | CYP2D6 96/4885CYP1A2 247/4885CYP2C19 35/4885 |
| US-20210228508-A1 | COMPOSITIONS AND METHODS THEREOF | CYP21A2, CYP2C19, CYP2F1 | CYP2D6 7/4885CYP1A2 15/4885CYP2C19 2/4885 |
| US-20050027119-A1 | Process for producing benzoxazine derivative and production intermediate thereof | CYP4Z1, COASY, VAT1 | CYP2D6 29/4885CYP1A2 16/4885CYP2C19 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.